Edwards Lifesciences Co. (NYSE:EW) Position Boosted by Brighton Jones LLC

Brighton Jones LLC boosted its holdings in Edwards Lifesciences Co. (NYSE:EW) by 10.0% during the second quarter, HoldingsChannel.com reports. The fund owned 3,742 shares of the medical research company’s stock after acquiring an additional 339 shares during the period. Brighton Jones LLC’s holdings in Edwards Lifesciences were worth $346,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Allspring Global Investments Holdings LLC increased its stake in shares of Edwards Lifesciences by 4.4% during the first quarter. Allspring Global Investments Holdings LLC now owns 330,711 shares of the medical research company’s stock valued at $31,603,000 after acquiring an additional 14,087 shares during the period. Empowered Funds LLC grew its holdings in shares of Edwards Lifesciences by 151.2% during the 1st quarter. Empowered Funds LLC now owns 20,123 shares of the medical research company’s stock valued at $1,923,000 after acquiring an additional 12,112 shares in the last quarter. Cetera Advisors LLC boosted its holdings in Edwards Lifesciences by 175.1% in the first quarter. Cetera Advisors LLC now owns 38,090 shares of the medical research company’s stock worth $3,640,000 after purchasing an additional 24,242 shares in the last quarter. TD Asset Management Inc boosted its holdings in Edwards Lifesciences by 95.1% in the fourth quarter. TD Asset Management Inc now owns 1,323,611 shares of the medical research company’s stock worth $100,925,000 after purchasing an additional 645,204 shares in the last quarter. Finally, Sei Investments Co. boosted its holdings in Edwards Lifesciences by 10.8% in the fourth quarter. Sei Investments Co. now owns 558,031 shares of the medical research company’s stock worth $42,550,000 after purchasing an additional 54,595 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

Insider Activity at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $93.29, for a total value of $466,450.00. Following the completion of the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at $4,378,659.44. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $93.29, for a total value of $466,450.00. Following the completion of the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at $4,378,659.44. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP Daveen Chopra sold 1,250 shares of Edwards Lifesciences stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total transaction of $87,437.50. Following the completion of the transaction, the vice president now directly owns 29,333 shares of the company’s stock, valued at approximately $2,051,843.35. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 16,250 shares of company stock valued at $1,218,138. Corporate insiders own 1.29% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on EW shares. Wells Fargo & Company cut their target price on shares of Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating for the company in a research report on Monday, September 9th. Evercore ISI lowered their target price on shares of Edwards Lifesciences from $91.00 to $76.00 and set an “in-line” rating on the stock in a research note on Thursday, July 25th. Oppenheimer reaffirmed an “outperform” rating and set a $90.00 price objective on shares of Edwards Lifesciences in a research note on Thursday, September 12th. Daiwa Capital Markets raised shares of Edwards Lifesciences from a “neutral” rating to an “outperform” rating in a research note on Wednesday, July 31st. Finally, Stifel Nicolaus decreased their price target on shares of Edwards Lifesciences from $85.00 to $70.00 and set a “hold” rating on the stock in a research note on Thursday, July 25th. Sixteen investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $79.82.

Edwards Lifesciences Trading Down 0.6 %

Shares of NYSE:EW opened at $66.83 on Monday. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The company has a quick ratio of 2.87, a current ratio of 3.71 and a debt-to-equity ratio of 0.08. The company’s fifty day simple moving average is $69.89 and its 200 day simple moving average is $82.80. The firm has a market cap of $40.27 billion, a price-to-earnings ratio of 28.81, a PEG ratio of 2.85 and a beta of 1.13.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Wednesday, July 24th. The medical research company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. The business had revenue of $1.63 billion for the quarter, compared to analyst estimates of $1.65 billion. Edwards Lifesciences had a net margin of 24.55% and a return on equity of 22.35%. The firm’s quarterly revenue was up 6.7% on a year-over-year basis. During the same period last year, the business posted $0.66 earnings per share. As a group, research analysts forecast that Edwards Lifesciences Co. will post 2.7 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.